India pharma sector to miss 2030 sales target amid tariff and shipping woes, trade body says

India's pharmaceutical industry is facing a significant setback in its growth plans. A leading trade body has revised its sales forecast for the sector, suggesting it will fall short of a previous ambitious target. The industry had aimed to reach $130 billion in sales by 2030, but new challenges have forced a downward adjustment.

This revised outlook highlights the mounting hurdles facing the sector. Ongoing tariff disputes and disruptions in global shipping networks are creating headwinds for exporters. These issues are making it harder for Indian drugmakers to compete internationally and expand their market reach.

For investors, this development signals a period of caution. The sector's growth trajectory has been altered by external factors, which may impact the performance of listed pharmaceutical companies. Market participants will likely keep a close watch on policy changes and global trade developments to gauge the sector's future path.